# Esreboxetine PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/esreboxetine

> Esreboxetine, sponsored by Axsome Therapeutics, Inc. (AXSM): 5 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | esreboxetine |
| Codes | AXS-14 |
| Sponsor | Axsome Therapeutics, Inc. (AXSM) https://sec-api.dev/companies/axsm/catalysts |
| Indications | [fibromyalgia](https://sec-api.dev/indications/fibromyalgia) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Nov 2024: NDA/BLA submission

- Status: scheduled. Date confidence: month.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124546): "NDA submission for AXS-14 for the management of fibromyalgia anticipated November 2024" https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124546): "Fibromyalgia: Axsome is completing preparations for the submission of the NDA for AXS-14 for the management of fibromyalgia and expects to submit the NDA to the FDA in November 2024." https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-ex99_1.htm

### Q1 2025: NDA/BLA submission

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2025-02-18, last confirmed 2025-02-18.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-021801): "Fibromyalgia: Axsome plans to submit an NDA to the FDA for AXS-14 for the management of fibromyalgia in the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-021801): "Positive clinical data demonstrate statistically significant improvements in symptoms of fibromyalgia ~1,000 individuals with fibromyalgia dosed with esreboxetine across Phase 2 and Phase 3 clinical trials for up to 14 weeks Statistically significant and clinically meaningful reductions in pain scores, overall symptom severity, and improvements in patient-reported global functioning and fatigue p<0.001 p<0.001 p=0.025 Phase 3 Efficacy Results (N=1,122) p<0.001 p<0.001 p=0.023 NDA submission anticipated 1Q 2025" https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_2.htm

### Jun 2025: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2025-08-04, last confirmed 2025-08-04.
- SEC Form 10-Q (accession 0000950170-25-102148): "We have submitted an NDA to the FDA for AXS-14 for the management of fibromyalgia and, in June 2025, announced that we received a Refusal to File letter from the FDA for the NDA." https://www.sec.gov/Archives/edgar/data/1579428/000095017025102148/axsm-20250630.htm

### Q4 2025: trial start

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-08-04, last confirmed 2025-11-03.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-261651): "Fibromyalgia: Axsome plans to initiate a Phase 3, fixed-dose, 12-week, placebo-controlled trial of AXS-14 in fibromyalgia in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1579428/000119312525261651/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-261651): "Rapid and robust efficacy demonstrated in Phase 2 and Phase 3 trials of AXS-14 in fibromyalgia Baseline * * *** * ** *** *** ** *** *** **** **** **** p<0.05 * p<0.01 ** p<0.001 *** p<0.0001 **** *** *** **** Baseline * ** *** *** *** ** *** *** ** **** Baseline * * Pain reduction Phase 3 efficacy results (N=1,122) Efficacy and safety of AXS-14 compared to placebo evaluated in >1,000 individuals with fibromyalgia across Phase 2 and Phase 3 clinical trials for up to 14 weeks Rapid and significant reductions in pain scores, improvements in patient-reported global functioning, fatigue, and overall symptom severity Initiation of new Phase 3 trial anticipated in 4Q 2025" https://www.sec.gov/Archives/edgar/data/1579428/000119312525261651/axsm-ex99_2.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-101624): "Fibromyalgia: To address the FDA's feedback in the previously disclosed Refusal to File (RTF) letter for the Company's NDA for AXS-14 for the management of fibromyalgia, Axsome plans to initiate a Phase 3, fixed-dose, 12-week trial of AXS-14 in fibromyalgia in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1579428/000095017025101624/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-101624): "Statistically significant improvements in key symptoms of fibromyalgia in Phase 2 and Phase 3 trials of AXS-14 Baseline * * *** * ** *** *** ** *** *** **** **** **** p<0.05 * p<0.01 ** p<0.001 *** p<0.0001 **** *** *** **** Baseline * ** *** *** *** ** *** *** ** **** Baseline * * Pain reduction Phase 3 efficacy results (N=1,122) Efficacy and safety of AXS-14 compared to placebo evaluated in >1,000 individuals with fibromyalgia across Phase 2 and Phase 3 clinical trials for up to 14 weeks Rapid and significant reductions in pain scores, improvements in patient-reported global functioning, fatigue, and overall symptom severity Initiation of Phase 3 trial anticipated in 4Q 2025" https://www.sec.gov/Archives/edgar/data/1579428/000095017025101624/axsm-ex99_2.htm

### Jan 2026: trial start

- Status: completed. Date confidence: month. Stage: 3. Indication: fibromyalgia.
- First seen 2026-02-23, last confirmed 2026-11-02.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-062421): "Fibromyalgia: In January 2026, Axsome initiated the FORWARD study, a Phase 3, double-blind, placebo-controlled, randomized withdrawal trial evaluating the efficacy and safety of AXS-14 for the management of fibromyalgia." https://www.sec.gov/Archives/edgar/data/1579428/000119312526062421/axsm-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-443752): "In January 2026, we initiated the FORWARD study, a Phase 3, double-blind, placebo-controlled, multicenter, randomized withdrawal trial of AXS-14 in patients with fibromyalgia." https://www.sec.gov/Archives/edgar/data/1579428/000119312526443752/axsm-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-342360): "In January 2026, we initiated the FORWARD study, a Phase 3, double-blind, placebo-controlled, multicenter, randomized withdrawal trial of AXS-14 in patients with fibromyalgia." https://www.sec.gov/Archives/edgar/data/1579428/000119312526342360/axsm-20260630.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/esreboxetine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Esreboxetine PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/esreboxetine

```bibtex
@misc{secapidev_pdufa_esreboxetine_20261116,
  title        = {Esreboxetine PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/esreboxetine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_esreboxetine_20261116","title":"Esreboxetine PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/esreboxetine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
